ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2731

Clinical Characteristics and Outcomes of ANCA-Vasculitides Associated Renal Disease in a Multi-Ethnic Population from a County Hospital

Shilpa Arora1, Ambrish Athavale2 and Peter Hart2, 1Medicine, John H Jr Stroger Hospital of Cook County, Chicago, IL, 2John H Jr Stroger Hospital of Cook County, Chicago, IL

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: ANCA, outcomes and renal disease

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 23, 2018

Title: Vasculitis – ANCA-Associated Poster II

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Antineutrophil cytoplasmic autoantibody (ANCA)-associated vasculitides include granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and renal-limited vasculitis (RLV). We aimed to study the clinical features and renal outcomes of ANCA vasculitides patients in a county hospital.

Methods: 37 consecutive patients with biopsy proven glomerulonephritis related to ANCA vasculitides were included to participate in the study. IRB approval was taken. Patients with minimum follow up of 6 months were considered to be eligible. Data was collected through retrospective medical chart reviews including on demographics, ANCA type and titers, other organ involvement, kidney biopsy findings, treatment received, baseline and follow up at creatinine at 6 months, and outcomes with respect to renal function, and death. Chi-square and t-tests were done to study correlates of crescentic glomerulonephritis, progression to ESRD and mortality.

Results: Mean (SD) age was 54 years (14) with 21 female and 16 male patients. Almost half of the patients (17/37; 46%) were of Hispanic origin (Table 1). Clinical diagnosis was MPA in 16/37 (43%) patients while 10/37 (27%) had GPA, and rest 11/37 (30%) had RLV. Serology was positive for pANCA in 22/37 (59.5%) patients and rest were cANCA positive (12/37; 32.4%). 36/37 (97.3%) patients had hematuria on their urinalysis with 12/37 (32%) having nephrotic range proteinuria (>3.5 g). 27/37 (73%) patients had crescents on kidney biopsy. Pulmonary involvement was seen in over 50% patients (19/37) with diffuse alveolar hemorrhage in 8/37 (21%). Most patients were treated with cyclophosphamide (35/37; 94.6%) with only 8/37 (21%) and 6/37 (16%) being treated with plasmapheresis and rituximab, respectively. Mean (95% CI) baseline and 6 month follow up creatinine were 4.93 (3.65 – 6.22) and 2.82 (1.95 – 3.69), respectively. Median (IQR) follow up was 22 (12-53) months. 10 out of 37 patients (27%) progressed to ESRD and needed dialysis. Mean time (SD) to progression to ESRD was 9.05 (5.08) months. Gender, ethnicity, ANCA type and titers did not predict crescentic glomerulonephritis on kidney biopsy. Crescentic glomerulonephritis did not predict progression to ESRD but correlated with mortality (P value 0.002). Degree of fibrosis on renal biopsy also did not correlate with progression to ESRD but predicted mortality (P value 0.03).

Conclusion: Crescentic glomerulonephritis was more common in this multi-ethnic population. Crescentic glomerulonephritis and degree of fibrosis on kidney biopsy did not predict progression to ESRD but correlated with mortality.

Table 1: Clinical characteristics and outcomes of ANCA related vasculitides associated renal disease

Age

54.40 ± 14.22 (Mean ± SD)

Gender

Female

21/37 (56.8%)

Male

16/37 (43.2%)

Ethnicity

Caucasian

6/37 (16.2%)

African American

7/37 (18.9%)

Hispanic

17/37 (45.9%)

Asian

4/37 (10.8%)

Other

3/37 (8.1%)

Diagnosis

GPA

10/37 (27%)

MPA

16/37 (43%)

Isolated renal AAV

11/37 (29.7%)

Serology

pANCA

22/37 (59.5%)

cANCA

12/37 (32.4%)

ANCA titer

104.07 ± 34.14 (Mean ± SD)

Urinalysis findings

Hematuria

36/37 (97.3%)

Nephrotic range proteinuria

12/37 (32.4%)

Renal biopsy findings

Crescentic glomerulonephritis

27/37 (73.0%)

Fibrosis

50%, 40-75% (Median, IQR)

Lung involvement

19/37 (51.4%)

Diffuse alveolar hemorrhage

8/37 (21.6%)

Treatment

Plasmapheresis

8/37 (21.6%)

Cyclophosphamide

35/37 (94.6%)

Rituximab

6/37 (16.2%)

Renal outcomes

Baseline creatinine

4.93 (3.65-6.22) (Mean, 95%CI)

Follow up creatinine (at 6 months)

2.82 (1.95-3.69) (Mean, 95%CI)

Progression to ESRD

10/37 (27.0%)

Mortality

3/37 (8.1%)


Disclosure: S. Arora, None; A. Athavale, None; P. Hart, None.

To cite this abstract in AMA style:

Arora S, Athavale A, Hart P. Clinical Characteristics and Outcomes of ANCA-Vasculitides Associated Renal Disease in a Multi-Ethnic Population from a County Hospital [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/clinical-characteristics-and-outcomes-of-anca-vasculitides-associated-renal-disease-in-a-multi-ethnic-population-from-a-county-hospital/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/clinical-characteristics-and-outcomes-of-anca-vasculitides-associated-renal-disease-in-a-multi-ethnic-population-from-a-county-hospital/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology